Towards a non-invasive molecular test for bladder cancer

膀胱癌的非侵入性分子检测

• 批准号: 7305500
• 负责人: Steve Goodison
• 金额: $ 27.93万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7305500
• 关键词: Biological; Biological Assay; Biological Markers; Bladder; Bladder Neoplasm; Body Fluids; Cancer Detection; Characteristics; Chemistry; Clinic; Clinical; Complement; Complex; Cystoscopy; Cytology; Data; Detection; Development; Diagnosis; Diagnostic; Early Diagnosis; Generations; Glycoproteins; Gold; Health Care Costs; Healthcare Systems; Individual; Informatics; Invasive; Investigation; Lead; Liquid substance; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Maps; Medical Surveillance; Methods; Molecular; Molecular Profiling; Pathologic; Patients; Phase; Population; Procedures; Protein Isoforms; Proteins; Proteomics; Public Health; Recurrence; Sampling; Screening procedure; Standards of Weights and Measures; Techniques; Testing; Tumor Biology; Urinalysis; Urination; Urine; Urology; Validation; base; follow-up; high throughput analysis; improved; insight; novel; software development; tumor; two-dimensional; urinary

DESCRIPTION (provided by applicant): The recurrence phenomenon of superficial bladder tumors makes bladder cancer one of the most prevalent cancers world-wide and is therefore a great burden to healthcare systems. Patients with superficial tumors are under continued surveillance by routine cystoscopy examinations of the bladder for early detection of new tumor developments. This is due to the lack of clinically useful markers which can detect the presence of bladder cancer without invasive procedures. Consequently, the development of urinalysis assays using reliable diagnostic markers would be of tremendous benefit to both patients and healthcare systems. This proposal aims to define molecular signature(s) of bladder cancer based on proteomic expression profiles. The protein complement of urine samples will be profiled using a novel combination of two-dimensional, liquid-phase separation and downstream mass mapping techniques. Data comprised of both quantitative and structural information will be correlated with clinical and pathological parameters. Thus, the proposed investigation will identify molecular profiles which are indicative of the presence of bladder cancer. Public health impact: The project seeks insights that will enable improvements in the non-invasive diagnosis of bladder cancer, through analysis of naturally voided urine. This will avoid unnecessary cystoscopy and therefore reduce patient discomfort and reduce health costs. Furthermore, the establishment of an accurate urine-based assay could lead to the development of routine screening of the population.

描述（由申请人提供）：浅表性膀胱肿瘤的复发现象使膀胱癌成为世界范围内最常见的癌症之一，因此是医疗保健系统的巨大负担。浅表性肿瘤患者通过常规膀胱镜检查持续监测膀胱，以早期发现新的肿瘤发展。这是由于缺乏临床上有用的标志物，可以检测膀胱癌的存在，而无需侵入性程序。因此，使用可靠的诊断标志物的尿分析测定的开发将对患者和医疗保健系统两者都具有巨大的益处。该提案旨在基于蛋白质组表达谱来定义膀胱癌的分子特征。尿液样本的蛋白质补体将使用二维液相分离和下游质量映射技术的新组合进行分析。由定量和结构信息组成的数据将与临床和病理参数相关。因此，拟议的调查将确定分子概况，这是膀胱癌的存在指示。 公共卫生影响：该项目旨在通过分析自然排泄的尿液，寻求能够改善膀胱癌非侵入性诊断的见解。这将避免不必要的膀胱镜检查，从而减少患者的不适并降低健康成本。此外，建立一个准确的尿液为基础的分析可能会导致人口的常规筛查的发展。